Royalty Pharma plc held its 2025 Annual General Meeting and Special Meeting of Shareholders on May 12, 2025. Shareholders approved several proposals, including the Membership Interest Purchase Agreement and related transactions, the authorization for the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor, the re-appointment of Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor, and the authorization for the Board of Directors to allot shares. However, not all proposals were approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.